Sofosbuvir-velpatasvir-voxilaprevir is a pangenotypic regimen for chronic HCV infection. In the USA and Europe, sofosbuvir-velpatasvir-voxilaprevir once daily for 12 weeks is indicated for adults who previously received an HCV NS5A inhibitor. In Europe, sofosbuvir-velpatasvir-voxilaprevir is also indicated in the absence of prior HCV direct-acting antiviral (DAA) therapy as an 8-week or 12-week regimen. In an open-label study, we evaluated the safety, efficacy, and pharmacokinetics of sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years with chronic HCV of any genotype.
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection / Indolfi, Guiseppe; Kelly, Deirdre; Nebbia, Gabriella; Iorio, Raffaele; Mania, Anna; Giacomet, Vania; Szenborn, Leszek; Shao, Jiang; Sang Yue, Mun; Hsueh, Chia-Hsiang; Parhy, Bandita; Kersey, Kathryn; Mangia, Alessandra; Pawlowska, Malgorzata; Bansal, Sanjay. - In: HEPATOLOGY. - ISSN 1527-3350. - (2022). [10.1002/hep.32393]
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection
Raffaele Iorio;
2022
Abstract
Sofosbuvir-velpatasvir-voxilaprevir is a pangenotypic regimen for chronic HCV infection. In the USA and Europe, sofosbuvir-velpatasvir-voxilaprevir once daily for 12 weeks is indicated for adults who previously received an HCV NS5A inhibitor. In Europe, sofosbuvir-velpatasvir-voxilaprevir is also indicated in the absence of prior HCV direct-acting antiviral (DAA) therapy as an 8-week or 12-week regimen. In an open-label study, we evaluated the safety, efficacy, and pharmacokinetics of sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years with chronic HCV of any genotype.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.